|
1
|
Lee JB, Kim HR and Ha SJ: Immune
checkpoint inhibitors in 10 years: Contribution of basic research
and clinical application in cancer immunotherapy. Immune Netw.
22(e2)2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Carlino MS, Larkin J and Long GV: Immune
checkpoint inhibitors in melanoma. Lancet. 398:1002–1014.
2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Xia L, Liu Y and Wang Y: PD-1/PD-L1
blockade therapy in advanced non-small-cell lung cancer: Current
status and future directions. Oncologist. 24 (Suppl 1):S31–S41.
2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Postow MA, Sidlow R and Hellmann MD:
Immune-related adverse events associated with immune checkpoint
blockade. N Engl J Med. 378:158–168. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zhang L, Reynolds KL, Lyon AR, Palaskas N
and Neilan TG: The evolving immunotherapy landscape and the
epidemiology, diagnosis, and management of cardiotoxicity: JACC:
CardioOncology primer. JACC CardioOncol. 3:35–47. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Khoja L, Day D, Wei-Wu Chen T, Siu LL and
Hansen AR: Tumour- and class-specific patterns of immune-related
adverse events of immune checkpoint inhibitors: A systematic
review. Ann Oncol. 28:2377–2385. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Herbst RS, Giaccone G, de Marinis F,
Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z,
Geater S, et al: Atezolizumab for first-line treatment of
PD-L1-selected patients with NSCLC. N Engl J Med. 383:1328–1339.
2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhou C, Li M, Wang Z, An D and Li B:
Adverse events of immunotherapy in non-small cell lung cancer: A
systematic review and network meta-analysis. Int Immunopharmacol.
102(108353)2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wang DY, Salem JE, Cohen JV, Chandra S,
Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal
toxic effects associated with immune checkpoint inhibitors: A
systematic review and meta-analysis. JAMA Oncol. 4:1721–1728.
2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Heymach JV, Mitsudomi T, Harpole D,
Aperghis M, Jones S, Mann H, Fouad TM and Reck M: Design and
rationale for a phase III, double-blind, placebo-controlled study
of neoadjuvant durvalumab + chemotherapy followed by adjuvant
durvalumab for the treatment of patients with resectable stages II
and III non-small-cell lung cancer: The AEGEAN trial. Clin Lung
Cancer. 23:e247–e251. 2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Rodríguez-Abreu D, Powell SF, Hochmair MJ,
Gadgeel S, Esteban E, Felip E, Speranza G, De Angelis F, Dómine M,
Cheng SY, et al: Pemetrexed plus platinum with or without
pembrolizumab in patients with previously untreated metastatic
nonsquamous NSCLC: Protocol-specified final analysis from
KEYNOTE-189. Ann Oncol. 32:881–895. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bernstein MB, Krishnan S, Hodge JW and
Chang JY: Immunotherapy and stereotactic ablative radiotherapy
(ISABR): A curative approach? Nat Rev Clin Oncol. 13:516–524.
2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Grant MJ, Herbst RS and Goldberg SB:
Selecting the optimal immunotherapy regimen in driver-negative
metastatic NSCLC. Nat Rev Clin Oncol. 18:625–644. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Rubio-Infante N, Ramírez-Flores YA,
Castillo EC, Lozano O, García-Rivas G and Torre-Amione G:
Cardiotoxicity associated with immune checkpoint inhibitor therapy:
A meta-analysis. Eur J Heart Fail. 23:1739–1747. 2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Baldini C, Martin Romano P, Voisin AL,
Danlos FX, Champiat S, Laghouati S, Kfoury M, Vincent H,
Postel-Vinay S, Varga A, et al: Impact of aging on immune-related
adverse events generated by anti-programmed death (ligand)PD-(L)1
therapies. Eur J Cancer. 129:71–79. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Shah KP, Song H, Ye F, Moslehi JJ, Balko
JM, Salem JE and Johnson DB: Demographic factors associated with
toxicity in patients treated with anti-programmed cell death-1
therapy. Cancer Immunol Res. 8:851–855. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kanjanapan Y and Yip D: Characteristics
and risk factors for microbial infections during cancer immune
checkpoint therapy. Cancer Med. 9:9027–9035. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ksienski D, Truong PT, Croteau NS, Chan A,
Sonke E, Patterson T, Clarkson M, Hackett S and Lesperance M:
Immune related adverse events and treatment discontinuation in
patients older and younger than 75 years with advanced melanoma
receiving nivolumab or pembrolizumab. J Geriatr Oncol. 13:220–227.
2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Guzman-Prado Y, Ben Shimol J and Samson O:
Body mass index and immune-related adverse events in patients on
immune checkpoint inhibitor therapies: A systematic review and
meta-analysis. Cancer Immunol Immunother. 70:89–100.
2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Assumpção JAF, Pasquarelli-do-Nascimento
G, Duarte MSV, Bonamino MH and Magalhães KG: The ambiguous role of
obesity in oncology by promoting cancer but boosting antitumor
immunotherapy. J Biomed Sci. 29(12)2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Cortellini A, Bersanelli M, Santini D,
Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M,
Zoratto F, et al: Another side of the association between body mass
index (BMI) and clinical outcomes of cancer patients receiving
programmed cell death protein-1 (PD-1)/programmed cell death-ligand
1 (PD-L1) checkpoint inhibitors: A multicentre analysis of
immune-related adverse events. Eur J Cancer. 128:17–26.
2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
De Filippi R, Morabito F, Santoro A,
Tripepi G, D'Alò F, Rigacci L, Ricci F, Morelli E, Zinzani PL and
Pinto A: Body mass index is not associated with survival outcomes
and immune-related adverse events in patients with Hodgkin lymphoma
treated with the immune checkpoint inhibitor nivolumab. J Transl
Med. 19(489)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wood C, Lopez G, Zhao L, Li M, Surya N,
Patel S, Grogan M, Bertino E, Shields P, He K, et al: P78.05
Patterns of irAE during first line pembrolizumab for NSCLC:
Incidence, risk factors, and impact on clinical outcome. J Thorac
Oncol. 16 (Suppl 1):S639–S640. 2021.
|
|
24
|
Muthumalage T and Rahman I: Pulmonary
immune response regulation, genotoxicity, and metabolic
reprogramming by menthol- and tobacco-flavored e-cigarette
exposures in mice. Toxicol Sci. 193:146–165. 2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Abdelrahim M, Mamlouk O, Lin H, Lin J,
Page V, Abdel-Wahab N, Swan J, Selamet U, Yee C, Diab A, et al:
Incidence, predictors, and survival impact of acute kidney injury
in patients with melanoma treated with immune checkpoint
inhibitors: A 10-year single-institution analysis. Oncoimmunology.
10(1927313)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
GBD Chronic Kidney Disease Collaboration.
Global, regional, and national burden of chronic kidney disease,
1990-2017: A systematic analysis for the global burden of disease
study 2017. Lancet. 395:709–733. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Cortellini A, Buti S, Bersanelli M, Giusti
R, Perrone F, Di Marino P, Tinari N, De Tursi M, Grassadonia A,
Cannita K, et al: Evaluating the role of FAMIly history of cancer
and diagnosis of multiple neoplasms in cancer patients receiving
PD-1/PD-L1 checkpoint inhibitors: The multicenter FAMI-L1 study.
Oncoimmunology. 9(1710389)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Sorah JD, Rose TL, Radhakrishna R,
Derebail VK and Milowsky MI: Incidence and prediction of immune
checkpoint inhibitor-related nephrotoxicity. J Immunother.
44:127–131. 2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Akturk HK, Alkanani A, Zhao Z, Yu L and
Michels AW: PD-1 inhibitor immune-related adverse events in
patients with preexisting endocrine autoimmunity. J Clin Endocrinol
Metab. 103:3589–3592. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Haanen J, Ernstoff MS, Wang Y, Menzies AM,
Puzanov I, Grivas P, Larkin J, Peters S, Thompson JA and Obeid M:
Autoimmune diseases and immune-checkpoint inhibitors for cancer
therapy: Review of the literature and personalized risk-based
prevention strategy. Ann Oncol. 31:724–744. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Tang K, Tiu BC, Wan G, Zhang S, Nguyen N,
Leung B, Gusev A, Reynolds KL, Kwatra SG and Semenov YR:
Pre-existing autoimmune disease and mortality in patients treated
with anti-PD-1 and Anti-PD-L1 therapy. J Natl Cancer Inst.
114:1200–1202. 2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Oren O, Yang EH, Molina JR, Bailey KR,
Blumenthal RS and Kopecky SL: Cardiovascular health and outcomes in
cancer patients receiving immune checkpoint inhibitors. Am J
Cardiol. 125:1920–1926. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Noseda R, Ruinelli L, Gaag LCV and Ceschi
A: Pre-existing cardiovascular conditions as clinical predictors of
myocarditis reporting with immune checkpoint inhibitors: A vigibase
study. Cancers (Basel). 12(3480)2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kim PH, Suh CH, Kim HS, Kim KW, Kim DY,
Lee EQ, Aizer AA, Guenette JP and Huang RY: Immune checkpoint
inhibitor with or without radiotherapy in melanoma patients with
brain metastases: A systematic review and meta-analysis. Korean J
Radiol. 22:584–595. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Miyashita H, Mikami T, Satoi S, Cruz C and
Galsky MD: Incidence and risk of colitis with programmed death 1
versus programmed death ligand 1 inhibitors for the treatment of
cancer. J Immunother. 43:291–298. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Luoma AM, Suo S, Williams HL, Sharova T,
Sullivan K, Manos M, Bowling P, Hodi FS, Rahma O, Sullivan RJ, et
al: Molecular pathways of colon inflammation induced by cancer
immunotherapy. Cell. 182:655–671.e22. 2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Huang YF, Xie WJ, Fan HY and Du J:
Comparative risks of high-grade adverse events among FDA-approved
systemic therapies in advanced melanoma: Systematic review and
network meta-analysis. Front Oncol. 10(571135)2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zheng J, Huang B, Xiao L, Wu M and Li J:
Treatment- and immune-related adverse events of immune checkpoint
inhibitors in esophageal or gastroesophageal junction cancer: A
network meta-analysis of randomized controlled trials. Front Oncol.
12(821626)2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Shaverdian N, Lisberg AE, Bornazyan K,
Veruttipong D, Goldman JW, Formenti SC, Garon EB and Lee P:
Previous radiotherapy and the clinical activity and toxicity of
pembrolizumab in the treatment of non-small-cell lung cancer: A
secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol.
18:895–903. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Quhal F, Mori K, Bruchbacher A, Resch I,
Mostafaei H, Pradere B, Schuettfort VM, Laukhtina E, Egawa S,
Fajkovic H, et al: First-line Immunotherapy-based combinations for
metastatic renal cell carcinoma: A systematic review and network
meta-analysis. Eur Urol Oncol. 4:755–765. 2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Schoenfeld AJ, Arbour KC, Rizvi H, Iqbal
AN, Gadgeel SM, Girshman J, Kris MG, Riely GJ, Yu HA and Hellmann
MD: Severe immune-related adverse events are common with sequential
PD-(L)1 blockade and osimertinib. Ann Oncol. 30:839–844.
2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Que S, Feng W and Xu Y: Progress on
immunotherapy combined with chemotherapy, radiotherapy and targeted
therapy for brain metastasis of small cell lung cancer. J Chin
Oncol. 30:177–185. 2024.
|
|
43
|
Zhang Q and Xu H: Meta-analysis of
efficacy and adverse effects of different combination schemes of
PD-1/PD-L1 inhibitors in the treatment of ovarian cancer. Chin J
Clin Obstet Gynecol. 25:292–297. 2024.
|
|
44
|
Cheng Y, Yang F and Zhang Y: Research
progress of phototherapy combined with immune checkpoint inhibitors
in the treatment of tumors. Chin J Cancer Biother. 31:626–631.
2024.
|
|
45
|
Lizotte PH, Hong RL, Luster TA, Cavanaugh
ME, Taus LJ, Wang S, Dhaneshwar A, Mayman N, Yang A, Kulkarni M, et
al: A high-throughput immune-oncology screen identifies EGFR
inhibitors as potent enhancers of antigen-specific cytotoxic
T-lymphocyte tumor cell killing. Cancer Immunol Res. 6:1511–1523.
2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Mazzola R, Jereczek-Fossa BA, Franceschini
D, Tubin S, Filippi AR, Tolia M, Lancia A, Minniti G, Corradini S,
Arcangeli S, et al: Oligometastasis and local ablation in the era
of systemic targeted and immunotherapy. Radiat Oncol.
15(92)2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Galluzzi L, Spranger S, Fuchs E and
López-Soto A: WNT signaling in cancer immunosurveillance. Trends
Cell Biol. 29:44–65. 2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Du S, Zhou L, Alexander GS, Park K, Yang
L, Wang N, Zaorsky NG, Ma X, Wang Y, Dicker AP and Lu B: PD-1
modulates radiation-induced cardiac toxicity through cytotoxic T
lymphocytes. J Thorac Oncol. 13:510–520. 2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
L'Orphelin JM, Varey E, Khammari A, Dreno
B and Dompmartin A: Severe late-onset grade III-IV adverse events
under immunotherapy: A retrospective study of 79 cases. Cancers
(Basel). 13(4928)2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Ruste V, Goldschmidt V, Laparra A,
Messayke S, Danlos FX, Romano-Martin P, Champiat S, Voisin AL,
Baldini C, Massard C, et al: The determinants of very severe
immune-related adverse events associated with immune checkpoint
inhibitors: A prospective study of the French REISAMIC registry.
Eur J Cancer. 158:217–224. 2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Brumberger ZL, Branch ME, Klein MW, Seals
A, Shapiro MD and Vasu S: Cardiotoxicity risk factors with immune
checkpoint inhibitors. Cardiooncology. 8(3)2022.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Sher AF, Golshani GM and Wu S: Fatal
adverse events associated with pembrolizumab in cancer patients: A
meta-analysis. Cancer Invest. 38:130–138. 2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Llovet JM, Castet F, Heikenwalder M, Maini
MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX and Finn RS:
Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol.
19:151–172. 2022.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Lou S, Cao Z, Chi W, Wang X, Feng M, Lin
L, Ding Y, Liu K, Qu L, Zhao G, et al: The safety concerns
regarding immune checkpoint inhibitors in liver cancer patients
rising mainly from CHB. Front Pharmacol. 14(1164309)2023.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Liu W, Liu Y, Ma F, Sun B, Wang Y, Luo J,
Liu M and Luo Z: Peripheral blood markers associated with
immune-related adverse effects in patients who had advanced
non-small cell lung cancer treated with PD-1 inhibitors. Cancer
Manag Res. 13:765–771. 2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Zhao L, Li Y, Jiang N, Song X, Xu J, Zhu
X, Chen C, Kong C, Wang X, Zong D, et al: Association of blood
biochemical indexes and antibiotic exposure with severe
immune-related adverse events in patients with advanced cancers
receiving PD-1 inhibitors. J Immunother. 45:210–216.
2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Takada S, Murooka H, Tahatsu K, Yanase M,
Umehara K, Hashishita H, Toru H, Satoru M, Sagawa T, Fujikawa K, et
al: Identifying early predictive markers for immune-related adverse
events in nivolumab-treated patients with renal cell carcinoma and
gastric cancer. Asian Pac J Cancer Prev. 23:695–701.
2022.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Zhang W, Tan Y, Li Y and Liu J: Neutrophil
to Lymphocyte ratio as a predictor for immune-related adverse
events in cancer patients treated with immune checkpoint
inhibitors: A systematic review and meta-analysis. Front Immunol.
14(1234142)2023.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Drobni ZD, Zafar A, Zubiri L, Zlotoff DA,
Alvi RM, Lee C, Hartmann S, Gilman HK, Villani AC, Nohria A, et al:
Decreased absolute lymphocyte count and increased
neutrophil/lymphocyte ratio with immune checkpoint
inhibitor-associated myocarditis. J Am Heart Assoc.
9(e018306)2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Zhou JG, Wong AH, Wang H, Tan F, Chen X,
Jin SH, He SS, Shen G, Wang YJ, Frey B, et al: Elucidation of the
application of blood test biomarkers to predict immune-related
adverse events in atezolizumab-treated NSCLC patients using machine
learning methods. Front Immunol. 13(862752)2022.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Lozano AX, Chaudhuri AA, Nene A,
Bacchiocchi A, Earland N, Vesely MD, Usmani A, Turner BE, Steen CB,
Luca BA, et al: T cell characteristics associated with toxicity to
immune checkpoint blockade in patients with melanoma. Nat Med.
28:353–362. 2022.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Johnson DB, McDonnell WJ,
Gonzalez-Ericsson PI, Al-Rohil RN, Mobley BC, Salem JE, Wang DY,
Sanchez V, Wang Y, Chastain CA, et al: A case report of clonal
EBV-like memory CD4+ T cell activation in fatal
checkpoint inhibitor-induced encephalitis. Nat Med. 25:1243–1250.
2019.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Zamora C, Riudavets M, Anguera G,
Alserawan L, Sullivan I, Barba A, Serra J, Ortiz MA, Gallardo P,
Perea L, et al: Circulating leukocyte-platelet complexes as a
predictive biomarker for the development of immune-related adverse
events in advanced non-small cell lung cancer patients receiving
anti-PD-(L)1 blocking agents. Cancer Immunol Immunother.
70:1691–1704. 2021.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Das R, Bar N, Ferreira M, Newman AM, Zhang
L, Bailur JK, Bacchiocchi A, Kluger H, Wei W, Halaban R, et al:
Early B cell changes predict autoimmunity following combination
immune checkpoint blockade. J Clin Invest. 128:715–720.
2018.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Chao Y, Zhou J, Hsu S, Ding N, Li J, Zhang
Y, Xu X, Tang X, Wei T, Zhu Z, et al: Risk factors for immune
checkpoint inhibitor-related pneumonitis in non-small cell lung
cancer. Transl Lung Cancer Res. 11:295–306. 2022.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Costantini A, Takam Kamga P, Julie C,
Corjon A, Dumenil C, Dumoulin J, Ouaknine J, Giraud V, Chinet T,
Rottman M, et al: Plasma biomarkers screening by multiplex ELISA
assay in patients with advanced non-small cell lung cancer treated
with immune checkpoint inhibitors. Cancers (Basel).
13(97)2020.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Kaminska P, Tempes A, Scholz E and Malik
AR: Cytokines on the way to secretion. Cytokine Growth Factor Rev.
79:52–65. 2024.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Liu C, Chu D, Kalantar-Zadeh K, George J,
Young HA and Liu G: Cytokines: From clinical significance to
quantification. Adv Sci (Weinh). 8(e2004433)2021.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Marschner D, Falk M, Javorniczky NR,
Hanke-Müller K, Rawluk J, Schmitt-Graeff A, Simonetta F, Haring E,
Dicks S, Ku M, et al: MicroRNA-146a regulates immune-related
adverse events caused by immune checkpoint inhibitors. JCI Insight.
5(e132334)2020.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Friedlander P, Wood K, Wassmann K,
Christenfeld AM, Bhardwaj N and Oh WK: A whole-blood RNA
transcript-based gene signature is associated with the development
of CTLA-4 blockade-related diarrhea in patients with advanced
melanoma treated with the checkpoint inhibitor tremelimumab. J
Immunother Cancer. 6(90)2018.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Refae S, Gal J, Ebran N, Otto J,
Borchiellini D, Peyrade F, Chamorey E, Brest P, Milano G and
Saada-Bouzid E: Correction to: Germinal Immunogenetics predict
treatment outcome for PD-1/PD-L1 checkpoint inhibitors. Invest New
Drugs. 39:287–292. 2021.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Liu W, Ma F, Sun B, Liu Y, Tang H, Luo J,
Chen H and Luo Z: Intestinal microbiome associated with
immune-related adverse events for patients treated with anti-PD-1
inhibitors, a real-world study. Front Immunol.
12(756872)2021.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Levy M, Kolodziejczyk AA, Thaiss CA and
Elinav E: Dysbiosis and the immune system. Nat Rev Immunol.
17:219–232. 2017.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Okazaki T, Tanaka Y, Nishio R, Mitsuiye T,
Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N and
Honjo T: Autoantibodies against cardiac troponin I are responsible
for dilated cardiomyopathy in PD-1-deficient mice. Nat Med.
9:1477–1483. 2003.PubMed/NCBI View
Article : Google Scholar
|
|
75
|
Ji C, Roy MD, Golas J, Vitsky A, Ram S,
Kumpf SW, Martin M, Barletta F, Meier WA, Hooper AT, et al:
Myocarditis in cynomolgus monkeys following treatment with immune
checkpoint inhibitors. Clin Cancer Res. 25:4735–4748.
2019.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Bjursten S, Pandita A, Zhao Z, Fröjd C, Ny
L, Jensen C, Ullerstam T, Jespersen H, Borén J, Levin M, et al:
Early rise in brain damage markers and high ICOS expression in CD4+
and CD8+ T cells during checkpoint inhibitor-induced
encephalomyelitis. J Immunother Cancer. 9(e002732)2021.PubMed/NCBI View Article : Google Scholar
|
